Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 10 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Bowel functions and bile Acids in patients with irritable bowel syndrome

May's issue of Clinical Gastroenterology & Hepatology investigates bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.

News image

There is an unclear relationship among bowel symptoms, excretion of unconjugated fecal bile acid, and colonic transit in irritable bowel syndrome.

Dr Andrea Shin and colleagues measured total and main individual unconjugated fecal bile acid in fecal samples of patients with irritable bowel syndrome (IBS), and assessed relationships among stool frequency or consistency, fecal unconjugated fecal bile acid, and colonic transit.

The team examined 30 healthy volunteers, 31 subjects with irritable bowel syndrome with diarrhea, and 30 with irritable bowel syndrome with constipation.

The patients were placed on 4-day diets containing 100 g fat.

The researchers measured stool characteristics, total fecal unconjugated fecal bile acid and fat levels, and overall colonic transit. 

The team assessed univariate associations of total and individual levels of fecal unconjugated fecal bile acid with phenotype using the Kruskal-Wallis test, and associations between endpoints were assessed using Spearman correlations.

The research team assessed relationships between stool, colonic transit, and fecal total and secretory unconjugated fecal bile acid.

Total fecal unconjugated fecal bile acid was associated with phenotype
Clinical Gastroenterology and Hepatology

There was a significant association between total fecal unconjugated fecal bile acid and phenotype.

The team found that the association was greater for irritable bowel syndrome-D than irritable bowel syndrome-C, compared with controls.

The doctors noted that fecal levels of primary unconjugated fecal bile acid were higher in subjects with irritable bowel syndrome-D, compared with controls.

Levels of fecal secretory unconjugated fecal bile acid were lower in subjects with irritable bowel syndrome-C compared with controls, whereas levels of the nonsecretory unconjugated fecal bile acid, lithocholic acid, were higher.

The researchers found significant univariate associations between stool number and form and total fecal unconjugated fecal bile acid, fecal fat, and colonic transit at 24 and 48 hours after eating.

In the regression models, the relative contribution of colonic transit was consistently greater, and largely independent of the contribution of bile acids.

Dr Shin's team commented, "Measurements of individual unconjugated fecal bile acids identify changes associated with stool characteristics in patients with irritable bowel syndrome."

"These effects are independent of the effects of colonic transit."

Clin Gastroenterol Hepatol 2013
13 May 2013

Go to top of page Email this page Email this page to a colleague

 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us